Kidney Cancer Weekly

March 23, 2026

Videos

Peer-to-Peer Clinical Conversations

KIM-1 Biomarker Data from Adjuvant Immunotherapy Trials in Renal Cell Carcinoma - Wenxin Xu

Wenxin Xu

Pedro Barata hosts Wenxin Xu to discuss KIM-1 (Kidney Injury Molecule 1) as an emerging biomarker in renal cell carcinoma.

STELLAR-002 Trial: Zanzalintinib Combo Explored in Clear Cell RCC - Jad Chahoud

Jad Chahoud

Pedro Barata hosts Jad Chahoud to discuss the STELLAR-002 trial, evaluating zanzalintinib combinations in first-line clear cell renal cell carcinoma.

Beyond the Abstracts

Optimal Treatment Duration in Metastatic Renal Cell Carcinoma Patients Responding to Immune Checkpoint Inhibitors: Should We Treat Beyond Two Years? - Beyond the Abstract

Clinical, Pathologic, and Genetic Correlates of Nuclear Grade in von Hippel-Lindau-associated Renal Cell Carcinoma - Beyond the Abstract

Conference Coverage

SES AUA 2026: Assessing the Role of Girentuximab PET/CT in Clinical Decision-Making: Results from a National Survey of Urologic Oncologists

SES AUA 2026: Impact of Cytoreductive Nephrectomy for RCC with Tumor Thrombus: Results from the Intercontinental Collaboration of RCC

EAU 2026: Development of a Novel 68Ga-Labeled Radiotracer Targeting Carbonic Anhydrase IX for Diagnosis of Clear Cell Renal Cell Carcinoma

ASCO GU 2026: A Randomized Phase 2 Trial of Nivolumab + Relatlimab + Ipilimumab Versus Nivolumab + Ipilimumab in First Line Advanced RCC

ASCO GU 2026: Phase 1b/2 KEYMAKER-U03 Substudy 03C of Belzutifan + Zanzalintinib or Belzutifan Monotherapy for Recurrent Clear Cell RCC During or After Anti-PD-(L)1 Therapy

Articles

Editor Selected Abstracts and Commentaries

Renal Cancer

Redo partial or radical nephrectomy for solitary renal recurrence after previous nephron-sparing surgery: Is functional preservation always justified?

Monogenic and Polygenic Risk for Kidney Cancer in Two Large Biobanks.

PARTIAL: study protocol for a clinical and cost-effectiveness of complex PARTIAL vs radical nephrectomy for clinically localised renal cell carcinoma randomised trial.

Angiogenesis-Informed Preoperative CT Radiogenomics Predicts Overall Survival in Clear Cell Renal Cell Carcinoma: Development and External Validation.

The Cyclin C-CDK8/19 Mediator kinase module controls PRCC-TFE3 driven senescence in renal epithelium and tumorigenesis in TFE3-RCC.

Survivorship after Kidney Cancer in Children, Adolescents and Young Adults- What is Causing Death and When?

Percutaneous Cryoablation of Clinical T1b Renal Tumors: A Tertiary Cancer Center Experience.

A Minimum 3-Year Follow-Up of Nivolumab-Plus-Ipilimumab in Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma: A Final Analysis of the J-ENCORE Study.

A Survey of Oncologists' Perceptions and Opinions Regarding Brain Imaging in Metastatic Renal Cell Carcinoma Within the UK.

Large sarcomatoid chromophobe renal cell carcinoma with tumor thrombus extending into the inferior vena cava: a case report on the challenges and lessons from a fatal outcome.

Impact of Perioperative Proton Pump Inhibitors on Renal Cancer Progression. A Retrospective Study.

Surgical Management of Nonmetastatic Renal Cell Carcinoma with Inferior Vena Cava Thrombus: A Systematic Review and Network Meta-analysis - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC